Introducing SPRAVATO® at Hoskinson Health & Wellness Clinic
Strategic Integration of a Regulated Pharmaceutical Therapy
Overview
Hoskinson Health & Wellness Clinic expanded its mental health services with the introduction of SPRAVATO® (esketamine), an FDA-approved treatment for adults with treatment-resistant depression. As a REMS-certified facility, Hoskinson Health required patient-facing communications that met rigorous clinical and regulatory standards, reflected the complexity of advanced mental health care, and aligned with the clinic’s established treatment philosophy.
Quaintise partnered with Hoskinson Health to develop a comprehensive introduction strategy from concept through execution, designed to educate patients, support informed decision-making, and integrate SPRAVATO® seamlessly into the clinic’s broader behavioral health offerings.
The Objective
The introduction of SPRAVATO® required more than awareness-building. The objective was to establish a disciplined communication framework that reflected the clinical rigor and regulatory oversight of a REMS-governed pharmaceutical therapy, clearly articulating appropriate patient criteria, treatment parameters, and how SPRAVATO® integrates within a comprehensive behavioral health care model.
Key Objectives
Creating a patient-centered voice and aesthetic aligned with the lived experience of individuals with Treatment-Resistant Depression (TRD)
Ensuring accuracy, compliance, and clinical integrity across all materials
Incorporating authentic patient testimonials and experiential elements to build social proof and trust
Positioning SPRAVATO® within Hoskinson Health’s integrated mental health services
Clearly communicating a highly regulated, FDA-approved treatment pathway
Creating a cohesive patient journey from awareness through consultation
Scope of Engagement
- Mental health service positioning and introduction of a regulated psychiatric therapy
- Content strategy and messaging architecture
- Patient brochure copywriting and design
- Educational email campaign development
- Website copy, structure, and visual direction
- Clinical review and accuracy vetting
- Alignment with REMS requirements and approved language
- Integration with existing behavioral health offerings, including TMS
Strategic Approach from Concept to Clinical Integration
The engagement followed a disciplined, end-to-end process to ensure clarity, credibility, and continuity across all touchpoints.
- Clinical grounding: All messaging was developed using FDA-approved language, in collaboration with senior representatives at Johnson & Johnson, and reviewed for clinical accuracy
- Audience calibration: Content balanced medical clarity with a compassionate, patient-centered tone
- Integrated positioning: SPRAVATO® was presented as one component of a broader mental health care continuum
- Consistency across channels: Brochure, email, and web content functioned as an integrated omnichannel communication framework
Creative Development & Execution
- Clinical articulation: Focused on eligibility criteria, supervision parameters, and treatment context
- Tone calibration: Avoided marketing language in favor of reassurance, transparency, and professionalism
- Design alignment: Visual standards matched Hoskinson Health’s established brand and care environment
- Journey support: Materials anticipated patient questions and reduced uncertainty at each step
Deliverables
Patient Education Brochure
Comprehensive, clinician-reviewed print and digital brochure explaining SPRAVATO®, the treatment process, benefits, care environment, and its role within an integrated mental health program, including coordinated use with Transcranial Magnetic Stimulation (TMS)
Email Outreach Campaign
Educational announcements introducing SPRAVATO® and encouraging informed conversations with care providers
Website Copy & Design
Dedicated SPRAVATO® web content integrated into Hoskinson Health’s mental health services, reflecting both standalone treatment and coordinated care pathways
impact
The SPRAVATO® introduction established a clear and credible foundation for responsible integration of a branded, REMS-governed therapy within a community-based clinical environment.
Patients were met with consistent, accurate information across channels—supporting informed conversations, appropriate expectations, and confident next steps. The materials reinforced Hoskinson Health’s commitment to evidence-based care while expanding access to advanced treatment options for individuals with complex mental health needs.
Rather than a one-time introduction, Hoskinson Health gained a repeatable framework for introducing future behavioral health services with the same level of clinical integrity and patient trust.
Why Quaintise
This strategic introduction of SPRAVATO® required deep understanding of mental health care, regulatory nuance, and patient psychology.
- Fluency in pharmaceutical communications, including REMS-aligned messaging and regulatory-sensitive content development
- Ability to collaborate with Johnson & Johnson to produce visually compelling, patient-friendly marketing assets
- Experience translating complex, branded therapies into responsible, patient-ready education
- Discipline in clinical accuracy, content validation, and regulatory alignment
- Strategic understanding of how advanced treatments integrate within broader behavioral health programs
- Expertise in guiding the introduction of a new clinical pharmaceutical service through structured, patient-centered communication
Summary
This case study demonstrates how Quaintise brings pharmaceutical fluency, regulatory literacy, and disciplined, patient-centered communication to the introduction of advanced therapies, ensuring new clinical offerings are presented with clarity, credibility, and responsibility.
